Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports ...
Hosted on MSN2d
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseWall Street expects a year-over-year increase in earnings on higher revenues when Amicus Therapeutics (FOLD) reports results for the quarter ended December 2024. While this widely-known consensus ...
PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at ...
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and Pombiliti® + Opfolda® Total Revenue Growth of 17-24% at CER ...
SG Americas Securities LLC cut its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 18.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor ...
Amicus Therapeutics, Inc. PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback